QQ客服 官方微博 反馈留言

	The Efficacy and Safety of Ipriflavone in Postmenopausal Women with Osteopenia or Osteoporosis: A Systematic Review and Meta-analysis
	Lili Chen; Xiaoya Zhou; Songlin Peng; Haobo Pan; Victor Y Leung; Qiang Luo; Juan Li; Zhihe Zhao; Shishu Huang; William W Lu
	2015
会议名称	2015国际华人骨研学会ICMRS-美国骨矿研究学会ASBMR大会
会议地点	湖南长沙
英文摘要	Background Ipriflavone (IP), a synthesized derivative of isoflavone, is one of over-the-counter drugs for prevention of osteoporosis (OP) since 1989 in over 22 countries. Although clinical trials have proved that IP is beneficial for the prevention and treatment of OP, its efficacy and safety are not in certainty due to some contradictory reports. With the wide usage of IP in osteoporotic women, it is therefore necessary to give a systematic review and meta-analysis for further evaluation. Methods We searched randomized control trials (RCTs) in PubMed and CENTRAL which used the regimen of IP in postmenopausal women with osteopenia or osteoporosis. The efficacy referred to the absolute change (grams per square centimeter), relative change (in percent) in BMD and bone turnover markers. The safety profiles were associated with adverse events and the number of subject withdrawals due to adverse reactions. Meta-analysis pooled the standard mean difference (SMD) of BMD in lumbar spine, subgroup analysis, and odds ratio (OR). Results Ten RCTs (n=1605) met the eligibility criteria were included in this systematic review. The increase of BMD in lumbar spine of the IP group was greater than that of the placebo group (random effect model: SMD=0.36; 95%CI= (0.09, 0.62)). For safety profile, most frequent reactions were gastrointestinal symptoms, but withdrawals because of adverse reaction were similar in the IP group compared to placebo control at the same time interval (7 studies, 2 years, fixed effect OR (95%CI) =1.12 (0.83 to 1.50), p=0.49, I2=0). Conclusion We found that IP significantly increases BMD and has inhibitory effect on bone resorption markers in the postmenopausal women with osteopenia or osteoporosis. Gastrointestinal symptoms may occur, but adverse drug withdrawal events were not statistically increased when compared with placebo group.
收录类别	其他
语种	英语
内容类型	会议论文
源URL	[http://ir.siat.ac.cn:8080/handle/172644/7468]
专题	深圳先进技术研究院_医药所
作者单位	2015
推荐引用方式 GB/T 7714	Lili Chen,Xiaoya Zhou,Songlin Peng,et al. The Efficacy and Safety of Ipriflavone in Postmenopausal Women with Osteopenia or Osteoporosis: A Systematic Review and Meta-analysis[C]. 见:2015国际华人骨研学会ICMRS-美国骨矿研究学会ASBMR大会. 湖南长沙.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。